Showing 861 - 880 results of 1,516 for search '"breast cancer"', query time: 0.12s Refine Results
  1. 861
  2. 862

    Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data by David Weller, Usha Menon, Alina Zalounina Falborg, Henry Jensen, Andriana Barisic, Anne Kari Knudsen, David H Brewster, Victoria Cairnduff, Eva Grunfeld, Elizabeth Harland, Mats Lambe, Rebecca-Jane Law, Yulan Lin, Martin Malmberg, Donna Turner, Richard D Neal, Victoria White, Samantha Harrison, Peter Vedsted, Una MacLeod, Conan Donnelly, Anna Gavin, Jon Emery, Oliver Bucher, Jatinderpal Kalsi, Chantelle Anandan, Evangelia Ourania Fourkala, Therese Kearney, Marie-Louise Essink-Bot, Sigrun Saur Almberg, Breann Hawryluk, Jacqueline Kelly, Jackie Boylan, Jan Willem Coebergh, David Brewster, Stefan Bergström, Victoria Hammersley, Rebecca Bergin, Alina Zalounina Falborg, Andriana Barisi, Kerry Moore, Maria Rejmyr Davis

    Published 2022-12-01
    “…Objectives A growing body of evidence suggests longer time between symptom onset and start of treatment affects breast cancer prognosis. To explore this association, the International Cancer Benchmarking Partnership Module 4 examined differences in breast cancer diagnostic pathways in 10 jurisdictions across Australia, Canada, Denmark, Norway, Sweden and the UK.Setting Primary care in 10 jurisdictions.Participant Data were collated from 3471 women aged >40 diagnosed for the first time with breast cancer and surveyed between 2013 and 2015. …”
    Get full text
    Article
  3. 863
  4. 864

    Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, Fuxing Zhao, Zitao Li, Shifen Huang, Yongzhi Chen, Yingjian He, Yan Liu, Zijun Zhu, Yongxin Li, Jinming Li, Mengting Da, Hongnan Mo, Feng Du, Liang Cui, Jing Bai, Zhen Liu, Fei Ma, Jiuda Zhao

    Published 2025-02-01
    “…Abstract We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. …”
    Get full text
    Article
  5. 865

    Coal Worker's Pneumoconiosis Mimicking Lung Cancer in a 75‐Year‐Old Woman With a History of Breast Cancer: A Clinical Case Report by Yeganeh Pakbaz, Farzan Moodi

    Published 2025-01-01
    “…We present a case of CWP in a 75‐year‐old female with a history of breast cancer, initially suspected of lung cancer due to an incidental mass on chest radiography. …”
    Get full text
    Article
  6. 866
  7. 867
  8. 868
  9. 869

    LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model by Ken S. Rosenthal, Sarah Stone, Gary Koski, Daniel H. Zimmerman

    Published 2017-01-01
    “…The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66–74 H-2d CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human β2 microglobulin38–50 peptide). …”
    Get full text
    Article
  10. 870
  11. 871

    Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Callistemon citrinus Phenolics Exhibited Anticancer Properties against Three Breast Cancer Cell Lines by Rashid Ahmed, Muhammad Tariq, Irfan S. Ahmad, Hanafy Fouly, Fakhar-i-Abbas, Anwarul Hasan, Mosbah Kushad

    Published 2019-01-01
    “…Nanoencapsulated phenolics from C. citrinus extract, berberine, and combination of both enhanced their bioactivity against the three breast cancer cell lines by nearly 2-fold. Growth inhibition of cells was a linear curve relative to phenolic concentration, with a maximum inhibition of nearly 100% at 0.1 mg/ml compared to control.…”
    Get full text
    Article
  12. 872
  13. 873
  14. 874
  15. 875
  16. 876
  17. 877
  18. 878
  19. 879

    Proximity Labeling-Based Identification of MGAT3 Substrates and Revelation of the Tumor-Suppressive Role of Bisecting GlcNAc in Breast Cancer via GLA Degradation by Bowen Wang, Xin He, Yue Zhou, Zengqi Tan, Xiang Li, Feng Guan, Lei Lei

    Published 2025-01-01
    “…Furthermore, we observed that bisecting GlcNAc modification inhibits breast cancer progression by promoting the degradation of α-galactosidase A (GLA). …”
    Get full text
    Article
  20. 880